Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), teer decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), teer decrease (Expand Search)
-
3001
-
3002
-
3003
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
3004
-
3005
-
3006
-
3007
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
3008
-
3009
-
3010
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
3011
-
3012
-
3013
-
3014
-
3015
-
3016
-
3017
-
3018
-
3019
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: -
3020